4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1M | -$7M | 22.3% | -771.6% | -$7M | $150000 | $2M |
| 2024 | $607574 | -$8M | 36.7% | -1599.0% | -$6M | $150000 | $2M |
| 2023 | $253573 | -$4M | -87.1% | -2032.8% | -$5M | $150000 | $2M |
| 2022 | $223208 | -$6M | -93.7% | -784.2% | — | $17M | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $162092 | -$2M | 47.1% | -1292.5% | -$3M | $150030 | $3M |
| Dec '25 | $303385 | -$1M | 60.2% | -632.0% | -$2M | $150000 | $2M |
| Sep '25 | $437602 | -$2M | -22.9% | -531.4% | -$2M | $150000 | $4M |
| Jun '25 | $100932 | -$2M | 50.4% | -1590.0% | -$1M | $150000 | $2M |
| Mar '25 | $163552 | -$2M | 55.2% | -1168.4% | -$2M | $150000 | $3M |
| Dec '24 | $241635 | -$2M | 51.1% | -854.7% | -$2M | $150000 | $2M |
| Sep '24 | $135293 | -$2M | 17.4% | -1566.0% | -$2M | $150000 | $3M |
| Jun '24 | $124972 | -$4M | 28.3% | -3351.8% | — | $150000 | $2M |
| Mar '24 | $105674 | $430470 | 38.1% | -1270.4% | — | $150000 | — |
| Dec '23 | $125681 | -$2M | -16.4% | -1507.1% | -$119468 | $150000 | $2M |
| Sep '23 | $51188 | $4M | -39.1% | -2972.9% | — | $150000 | — |
| Jun '23 | $59532 | -$3M | -209.0% | -1323.7% | — | $150000 | — |
| Mar '23 | $17172 | -$3M | -325.8% | -5536.1% | — | — | — |
| Dec '22 | -$37174 | -$2M | 538.0% | 1841.9% | — | $17M | — |
| Sep '22 | $168185 | -$1M | 45.1% | -127.9% | — | — | — |
| Jun '22 | $45173 | -$2M | -92.9% | -1520.6% | — | — | — |
How the market has priced SXTP against its own fundamentals since 2023-07 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, 60 DEGREES PHARMACEUTICALS, INC.'s revenue has grown 65.2% per year. These are computed facts, not advice.
As of FY2025, 60 DEGREES PHARMACEUTICALS, INC. reported $150000 of total debt against $2M of cash; operating income covered interest expense -994.1×.
In FY2025, gross margin was 22.3%, operating margin -771.6%, and net margin -732.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.